• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

GSK-3 和 Tau:阿尔茨海默病中的关键二重奏。

GSK-3 and Tau: A Key Duet in Alzheimer's Disease.

机构信息

Instituto de Tecnologías Biomédicas (ITB), Universidad de La Laguna (ULL), 38200 Tenerife, Spain.

Centro de Biología Molecular Severo Ochoa (CBMSO), Consejo Superior de Investigaciones Científicas (CSIC) y la Universidad Autónoma de Madrid (UAM), 28049 Madrid, Spain.

出版信息

Cells. 2021 Mar 24;10(4):721. doi: 10.3390/cells10040721.

DOI:10.3390/cells10040721
PMID:33804962
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8063930/
Abstract

Glycogen synthase kinase-3 (GSK-3) is a ubiquitously expressed serine/threonine kinase with a plethora of substrates. As a modulator of several cellular processes, GSK-3 has a central position in cell metabolism and signaling, with important roles both in physiological and pathological conditions. GSK-3 has been associated with a number of human disorders, such as neurodegenerative diseases including Alzheimer's disease (AD). GSK-3 contributes to the hyperphosphorylation of tau protein, the main component of neurofibrillary tangles (NFTs), one of the hallmarks of AD. GSK-3 is further involved in the regulation of different neuronal processes that are dysregulated during AD pathogenesis, such as the generation of amyloid-β (Aβ) peptide or Aβ-induced cell death, axonal transport, cholinergic function, and adult neurogenesis or synaptic function. In this review, we will summarize recent data about GSK-3 involvement in these processes contributing to AD pathology, mostly focusing on the crucial interplay between GSK-3 and tau protein. We further discuss the current development of potential AD therapies targeting GSK-3 or GSK-3-phosphorylated tau.

摘要

糖原合酶激酶-3(GSK-3)是一种广泛表达的丝氨酸/苏氨酸激酶,其底物众多。作为多种细胞过程的调节剂,GSK-3 在细胞代谢和信号转导中处于中心地位,在生理和病理条件下都具有重要作用。GSK-3 与许多人类疾病有关,如包括阿尔茨海默病(AD)在内的神经退行性疾病。GSK-3 参与了 tau 蛋白的过度磷酸化,tau 蛋白是神经原纤维缠结(NFTs)的主要成分之一,也是 AD 的标志之一。GSK-3 还参与了 AD 发病过程中失调的不同神经元过程的调节,如淀粉样β(Aβ)肽的产生或 Aβ 诱导的细胞死亡、轴突运输、胆碱能功能、成年神经发生或突触功能。在这篇综述中,我们将总结最近关于 GSK-3 参与这些导致 AD 病理的过程的数据,主要集中在 GSK-3 和 tau 蛋白之间的关键相互作用上。我们还讨论了针对 GSK-3 或 GSK-3 磷酸化 tau 的潜在 AD 治疗方法的最新进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d4/8063930/010960519384/cells-10-00721-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d4/8063930/53a61c4645c9/cells-10-00721-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d4/8063930/f03b9d827f55/cells-10-00721-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d4/8063930/92a5ec781428/cells-10-00721-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d4/8063930/010960519384/cells-10-00721-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d4/8063930/53a61c4645c9/cells-10-00721-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d4/8063930/f03b9d827f55/cells-10-00721-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d4/8063930/92a5ec781428/cells-10-00721-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/14d4/8063930/010960519384/cells-10-00721-g004.jpg

相似文献

1
GSK-3 and Tau: A Key Duet in Alzheimer's Disease.GSK-3 和 Tau:阿尔茨海默病中的关键二重奏。
Cells. 2021 Mar 24;10(4):721. doi: 10.3390/cells10040721.
2
Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration.糖原合酶激酶-3与阿尔茨海默病、皮克病、进行性核上性麻痹和皮质基底节变性中的神经元和胶质细胞过度磷酸化tau蛋白沉积有关。
Acta Neuropathol. 2002 Dec;104(6):583-91. doi: 10.1007/s00401-002-0587-8. Epub 2002 Jul 13.
3
Roles of glycogen synthase kinase 3 in Alzheimer's disease.糖原合酶激酶 3 在阿尔茨海默病中的作用。
Curr Alzheimer Res. 2012 Sep;9(7):864-79. doi: 10.2174/156720512802455386.
4
Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.糖原合酶激酶-3 在阿尔茨海默病发病机制中的作用及糖原合酶激酶-3 抑制剂。
Expert Rev Neurother. 2010 May;10(5):703-10. doi: 10.1586/ern.10.40.
5
GSK-3 is essential in the pathogenesis of Alzheimer's disease.糖原合成酶激酶-3在阿尔茨海默病的发病机制中至关重要。
J Alzheimers Dis. 2006;9(3 Suppl):309-17. doi: 10.3233/jad-2006-9s335.
6
Axonal transport, tau protein, and neurodegeneration in Alzheimer's disease.阿尔茨海默病中的轴突运输、tau蛋白与神经退行性变
Neuromolecular Med. 2002;2(2):151-65. doi: 10.1385/NMM:2:2:151.
7
Abeta exacerbates the neuronal dysfunction caused by human tau expression in a Drosophila model of Alzheimer's disease.Abeta 加剧了人类 tau 表达在阿尔茨海默病果蝇模型中引起的神经元功能障碍。
Exp Neurol. 2010 Jun;223(2):401-9. doi: 10.1016/j.expneurol.2009.09.014. Epub 2009 Sep 24.
8
Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer's Disease.淀粉样前体蛋白和淀粉样 β 通过激活 Ras-ERK 信号通路和 GSK-3 促进阿尔茨海默病中的神经退行性变。
eNeuro. 2017 Mar 27;4(2). doi: 10.1523/ENEURO.0149-16.2017. eCollection 2017 Mar-Apr.
9
Truncation and activation of GSK-3β by calpain I: a molecular mechanism links to tau hyperphosphorylation in Alzheimer's disease.钙蛋白酶I对GSK-3β的截断和激活:一种与阿尔茨海默病中tau蛋白过度磷酸化相关的分子机制
Sci Rep. 2015 Feb 2;5:8187. doi: 10.1038/srep08187.
10
17beta-estradiol attenuates glycogen synthase kinase-3beta activation and tau hyperphosphorylation in Akt-independent manner.17β-雌二醇以不依赖Akt的方式减弱糖原合酶激酶-3β的激活和tau蛋白的过度磷酸化。
J Neural Transm (Vienna). 2008 Jun;115(6):879-88. doi: 10.1007/s00702-008-0021-z. Epub 2008 Jan 24.

引用本文的文献

1
Glycogen synthase kinase-3: the master switch driving neurodegeneration in Alzheimer's disease and Parkinson's disease.糖原合酶激酶-3:驱动阿尔茨海默病和帕金森病神经退行性变的主开关。
Arch Toxicol. 2025 Aug 28. doi: 10.1007/s00204-025-04174-1.
2
Integrated machine learning and deep learning-based virtual screening framework identifies novel natural GSK-3β inhibitors for Alzheimer's disease.基于机器学习和深度学习的集成虚拟筛选框架识别出用于阿尔茨海默病的新型天然GSK-3β抑制剂。
J Comput Aided Mol Des. 2025 Jul 16;39(1):53. doi: 10.1007/s10822-025-00637-w.
3
Proinflammatory transcriptomic and kinomic alterations in astrocytes derived from patients with familial Alzheimer's disease.

本文引用的文献

1
Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies.tau:多种脑部疾病的促成因子,也是迅速发展的治疗策略的靶标。
Science. 2021 Feb 26;371(6532). doi: 10.1126/science.abb8255.
2
Mechanisms and Therapeutic Implications of GSK-3 in Treating Neurodegeneration.GSK-3 在治疗神经退行性疾病中的作用机制及治疗意义。
Cells. 2021 Jan 29;10(2):262. doi: 10.3390/cells10020262.
3
Isoform-selective decrease of glycogen synthase kinase-3-beta (GSK-3β) reduces synaptic tau phosphorylation, transcellular spreading, and aggregation.
家族性阿尔茨海默病患者来源的星形胶质细胞中促炎转录组和激酶组的改变。
Brain Behav Immun Health. 2025 Jun 21;47:101044. doi: 10.1016/j.bbih.2025.101044. eCollection 2025 Aug.
4
Recent Advances in Antibody Therapy for Alzheimer's Disease: Focus on Bispecific Antibodies.阿尔茨海默病抗体治疗的最新进展:聚焦双特异性抗体
Int J Mol Sci. 2025 Jun 28;26(13):6271. doi: 10.3390/ijms26136271.
5
Research progress of platelets in neurodegenerative diseases.血小板在神经退行性疾病中的研究进展
Front Aging Neurosci. 2025 Jun 10;17:1544605. doi: 10.3389/fnagi.2025.1544605. eCollection 2025.
6
Navigating the treatment landscape of Alzheimer's disease: Current strategies and future directions.探索阿尔茨海默病的治疗前景:当前策略与未来方向
Ibrain. 2025 May 10;11(2):162-184. doi: 10.1002/ibra.12197. eCollection 2025 Summer.
7
Avenanthramide-C as Alzheimer's Disease-Modifying Therapy: Early and Sustained Intervention Prevents Disease Progression in Mouse Models.阿魏酸酰胺-C作为阿尔茨海默病的改善疗法:早期持续干预可预防小鼠模型中的疾病进展。
Cells. 2025 Jun 2;14(11):826. doi: 10.3390/cells14110826.
8
Exercise training exerts beneficial effects on Alzheimer's disease through multiple signaling pathways.运动训练通过多种信号通路对阿尔茨海默病产生有益影响。
Front Aging Neurosci. 2025 May 21;17:1558078. doi: 10.3389/fnagi.2025.1558078. eCollection 2025.
9
Dual impact of neuroinflammation on cognitive and motor impairments in Alzheimer's disease.神经炎症对阿尔茨海默病认知和运动障碍的双重影响。
J Alzheimers Dis Rep. 2025 Jun 2;9:25424823251341870. doi: 10.1177/25424823251341870. eCollection 2025 Jan-Dec.
10
Unlocking the neuroprotective potential of peptide nucleic acids 5 (PNA5) in neurological diseases: molecular mechanisms to therapeutic approaches.揭示肽核酸5(PNA5)在神经疾病中的神经保护潜力:从分子机制到治疗方法
Metab Brain Dis. 2025 May 29;40(5):213. doi: 10.1007/s11011-025-01629-3.
糖原合酶激酶-3β(GSK-3β)的亚型选择性降低可减少突触tau蛋白磷酸化、跨细胞扩散和聚集。
iScience. 2021 Jan 13;24(2):102058. doi: 10.1016/j.isci.2021.102058. eCollection 2021 Feb 19.
4
Tau Avoids the GTP Cap at Growing Microtubule Plus-Ends.微管蛋白在微管正端生长时避开GTP帽。
iScience. 2020 Nov 6;23(12):101782. doi: 10.1016/j.isci.2020.101782. eCollection 2020 Dec 18.
5
Discovery and Design of Novel Small Molecule GSK-3 Inhibitors Targeting the Substrate Binding Site.新型小分子 GSK-3 抑制剂靶向底物结合位点的发现与设计。
Int J Mol Sci. 2020 Nov 18;21(22):8709. doi: 10.3390/ijms21228709.
6
GSK3α, not GSK3β, drives hippocampal NMDAR-dependent LTD via tau-mediated spine anchoring.GSK3α 而非 GSK3β 通过 tau 介导的棘突锚定驱动海马 NMDA 受体依赖性 LTD。
EMBO J. 2021 Jan 15;40(2):e105513. doi: 10.15252/embj.2020105513. Epub 2020 Nov 16.
7
Mechanical injuries of neurons induce tau mislocalization to dendritic spines and tau-dependent synaptic dysfunction.神经元的机械损伤会导致 tau 蛋白向树突棘的异常定位和 tau 依赖性的突触功能障碍。
Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):29069-29079. doi: 10.1073/pnas.2008306117. Epub 2020 Nov 2.
8
Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer's disease.溶血磷脂酸与脑脊液生物标志物的关联及其与阿尔茨海默病进展的关系。
Alzheimers Res Ther. 2020 Oct 2;12(1):124. doi: 10.1186/s13195-020-00680-9.
9
Discovery and Functional Characterization of hPT3, a Humanized Anti-Phospho Tau Selective Monoclonal Antibody.发现并功能表征 hPT3:一种人源化抗磷酸化 Tau 选择性单克隆抗体。
J Alzheimers Dis. 2020;77(4):1397-1416. doi: 10.3233/JAD-200544.
10
GSK-3β regulates the synaptic expression of NMDA receptors via phosphorylation of phosphatidylinositol 4 kinase type IIα.GSK-3β 通过磷酸化磷脂酰肌醇 4 激酶 IIα 调节 NMDA 受体的突触表达。
Eur J Neurosci. 2021 Oct;54(8):6815-6825. doi: 10.1111/ejn.14841. Epub 2020 Jun 27.